<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon - Maltez, N - 2023 | Cochrane Library</title> <meta content="Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon - Maltez, N - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon - Maltez, N - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014089" name="dc.identifier" scheme="DOI"/> <meta content="Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon" name="citation_title"/> <meta content="Nancy Maltez" name="citation_author"/> <meta content="The Ottawa Hospital" name="citation_author_institution"/> <meta content="Lara J Maxwell" name="citation_author"/> <meta content="Faculty of Medicine, University of Ottawa" name="citation_author_institution"/> <meta content="Fadumo Rirash" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Elizabeth Tanjong Ghogomu" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Sarah E Harding" name="citation_author"/> <meta content="SUNY Upstate Medical University" name="citation_author_institution"/> <meta content="Paul C Tingey" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="George A Wells" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Peter Tugwell" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Janet Pope" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="janet.pope@sjhc.london.on.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD014089" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/11/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Pain; *Phosphodiesterase 5 Inhibitors [therapeutic use]; Sample Size; *Scleroderma, Systemic [complications, drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014089&amp;doi=10.1002/14651858.CD014089&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014089\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014089\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014089",title:"Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud\u0027s phenomenon",firstPublishedDate:"Nov 6, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Central Editorial Service",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014089&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014089';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014089/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014089/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014089%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014089/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014089/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014089/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014089/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014089" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014089/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014089" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014089/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014089/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2479 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014089" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014089/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/appendices#CD014089-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/supinfo/CD014089-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/supinfo/CD014089-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014089/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014089/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014089/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014089/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2025 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014089/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0004">Nancy Maltez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0005">Lara J Maxwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0006">Fadumo Rirash</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0007">Elizabeth Tanjong Ghogomu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0008">Sarah E Harding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0009">Paul C Tingey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0010">George A Wells</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0011">Peter Tugwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014089/information#CD014089-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Janet Pope</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014089/information/en#CD014089-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 November 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014089/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014089">https://doi.org/10.1002/14651858.CD014089</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014089-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014089-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014089-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014089-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014089-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014089-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014089-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014089-abs-0001" lang="en"> <section id="CD014089-sec-0001"> <h3 class="title" id="CD014089-sec-0001">Background</h3> <p>Raynaud's phenomenon is a vasodilatory phenomenon characterised by digital pallor, cyanosis, and pain of the extremities. Primary Raynaud's phenomenon has no underlying disease associated with it, while secondary Raynaud's phenomenon is associated with connective tissue disorders such as systemic sclerosis. Systemic sclerosis causes fibrosis and commonly affects the skin and internal organs such as the gastrointestinal tract, lungs, kidney, and heart. Phosphodiesterase 5 inhibitors (PDE5i) are a class of drugs that increases blood flow to the extremities and may be beneficial in the treatment of Raynaud's phenomenon. </p> </section> <section id="CD014089-sec-0002"> <h3 class="title" id="CD014089-sec-0002">Objectives</h3> <p>To assess the benefits and harms of PDE5i compared to placebo for the treatment of Raynaud's phenomenon. </p> </section> <section id="CD014089-sec-0003"> <h3 class="title" id="CD014089-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and clinical trial registries up to June 2022. We did not apply any language restrictions. We searched the bibliographies of retrieved articles and contacted key experts in the field for additional and unpublished data. </p> </section> <section id="CD014089-sec-0004"> <h3 class="title" id="CD014089-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing PDE5i to placebo in people with primary and secondary Raynaud's phenomenon. </p> </section> <section id="CD014089-sec-0005"> <h3 class="title" id="CD014089-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD014089-sec-0006"> <h3 class="title" id="CD014089-sec-0006">Main results</h3> <p>This review included nine RCTs which ranged in duration from four to eight weeks and included a total of 411 participants. The majority had Raynaud's phenomenon secondary to systemic sclerosis. Tadalafil was assessed in four studies, sildenafil in three studies, vardenafil in one study, and a new PDE5 inhibitor known as "PF‐00489791" in one study. Three studies were parallel design and six studies were cross‐over. </p> <p>The frequency of attacks per week was 24 with placebo and PDE5i reduced the frequency of attacks by an average of three attacks per week (mean difference (MD) ‐3.07, 95% confidence interval (CI) ‐5.15 to ‐1.00; 8 studies; low‐certainty evidence). The duration of attacks per day was 55 minutes with placebo and PDE5i reduced the duration of attacks by an average of five minutes (MD ‐5.31, 95% CI ‐8.90 to ‐1.71; 8 studies; low‐certainty evidence). Very low‐certainty evidence from one study with eight participants showed severity of Raynaud's attacks (assessed on a 10 cm visual analogue scale with lower scores indicating less severity) was 20% lower with a PDE5i (3.7 with placebo compared to 1.6 with treatment; MD ‐2.1, 95% CI ‐2.7 to 1.4; very low‐certainty evidence). </p> <p>Pain and patient global assessment were assessed on a 10 cm visual analogue scale with lower scores indicating improvement. Low‐certainty evidence showed that the use of PDE5i may result in little to no difference compared to placebo in reducing the average pain of Raynaud's attacks (3 to 2.9; MD ‐0.10, 95% CI ‐0.78 to 0.57; 4 studies). Global scores were 36% lower with the use of a PDE5i compared to placebo (9.2 to 5.6; MD ‐3.59, 95% CI ‐4.45 to ‐2.73; 1 study, 24 participants; low‐certainty evidence). </p> <p>The rate of withdrawals during treatment with PDE5i ranged from 2% to 20% compared with 2% to 4% in the placebo group in five studies. Four studies reported no withdrawals due to adverse events. Seven studies reported no serious adverse events. The rate of serious adverse events reported in two studies ranged from 2% during treatment to 4% with placebo. </p> <p>The majority of the studies were judged as low or unclear risk of bias for selection, performance, and detection bias. Almost half were judged at high risk of attrition bias and unclear risk for selective reporting bias. We downgraded frequency of attacks, duration of attacks, pain intensity, and patient global assessment for small sample sizes and concerns about inconsistency and graded each as low certainty of evidence. We downgraded severity of attacks to very low certainty due to serious concerns about imprecision and publication bias. We downgraded withdrawals due to adverse events and serious adverse events to moderate certainty of evidence due to a low number of reported events. </p> </section> <section id="CD014089-sec-0007"> <h3 class="title" id="CD014089-sec-0007">Authors' conclusions</h3> <p>Based on low‐certainty evidence, PDE5i may reduce the frequency of attacks of Raynaud's phenomenon by a small amount per week, result in a small reduction in the duration of attack, improve patients' global assessment of their disease, and result in little to no difference in pain. PDE5i probably result in little or no difference in serious adverse events but slightly increase the likelihood of withdrawing from treatment due to an adverse event. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014089-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014089-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014089-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014089-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014089-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014089-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014089-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014089-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014089-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014089-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014089-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014089-abs-0002" lang="en"> <h3>What are the benefits and harms of medicines that increase blood flow to the extremities (phosphodiesterase 5 inhibitors (PDE5i)) compared to placebo for the treatment of Raynaud's phenomenon? </h3> <p><b>Key messages</b> </p> <p>PDE5i may reduce slightly the frequency and duration of attacks of Raynaud's phenomenon, and may improve the patient's overall assessment of their disease, but may make little to no difference in pain compared to people taking a fake pill (placebo). It is unclear if PDE5i has an effect on the severity of an attack. </p> <p>Compared to people treated with placebo, people treated with PDE5i are more likely to stop treatment early but probably have similar rates of serious unwanted harms. </p> <p><b>What is Raynaud's phenomenon?</b> </p> <p>Raynaud's phenomenon is a disease that results in decreased blood flow to the fingers and toes. Symptoms include discolouration, pain, and in severe cases, ulceration (open sores) of the fingers or toes. Cold, stress, and emotional discomfort are the most common triggers of a Raynaud's attack. Primary Raynaud's phenomenon has no underlying disease associated with it, while secondary Raynaud's phenomenon is associated with underlying connective tissue diseases such as systemic sclerosis (scleroderma) or lupus (systemic lupus erythematosus). </p> <p><b>How is Raynaud's phenomenon treated?</b> </p> <p>Phosphodiesterase 5 inhibitors (PDE5i) are a class of medicines used in the treatment of erectile dysfunction and high blood pressure in the lungs. PDE5i may be effective in Raynaud's phenomenon by increasing blood flow to the extremities. The studies included in this review assessed four PDE5i medicines. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if PDE5i were better than a fake pill (placebo) to improve Raynaud's phenomenon. We also wanted to find out if PDE5i were associated with any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared PDE5i with placebo in people with Raynaud's phenomenon. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found nine studies on a total of 411 people, mostly female. Most of the people in the studies had Raynaud's phenomenon in addition to systemic sclerosis. Study duration ranged from four to eight weeks. Studies were conducted in India, Germany, and Brazil. </p> <p>We found that:</p> <p>‐ people who took a PDE5i experienced three fewer attacks in a week (21) than those who took placebo (24). </p> <p>‐ the average duration of Raynaud's phenomenon attacks was five minutes shorter with PDE5i compared to placebo (50 versus 55 minutes). </p> <p>‐ we are uncertain whether PDE5i reduces the severity of an attack</p> <p>‐ there may be little to no difference in the amount of pain in people who took PDE5i compared to those who took a placebo (2.9 compared to 3.0 points on a 0 to 10 scale which is a 1% improvement). </p> <p>‐ people who took a PDE5i reported a 36% overall improvement in their disease compared to those taking a placebo. </p> <p>‐ people who took a PDE5i probably have similar rates of serious unwanted events that cause harm compared to those taking a placebo (2% with PDE5i and 4% with placebo). </p> <p>‐ people who took a PDE5i are probably more likely to stop treatment early (range of 4% to 20% in different studies) compared to those taking a placebo (2%). </p> <p><b>What are the limitations of this evidence?</b> </p> <p>We have little confidence in the evidence because the studies were small and results varied widely. </p> <p><b>How up to date is this evidence?</b> </p> <p>This evidence is up to date to June 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014089-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014089-sec-0101"></div> <h3 class="title" id="CD014089-sec-0102">Implications for practice</h3> <section id="CD014089-sec-0102"> <p>Low‐certainty evidence from nine studies indicates that PDE5i may have some small benefit in reducing the frequency and duration of attacks in Raynaud's phenomenon secondary to systemic sclerosis. There were minimal data for participants with primary Raynaud's, but the results were consistent with secondary Raynaud's phenomenon. Use of PDE5i probably results in little or no difference in serious adverse events but slightly increases the likelihood of withdrawing from treatment due to an adverse event. </p> </section> <h3 class="title" id="CD014089-sec-0103">Implications for research</h3> <section id="CD014089-sec-0103"> <p>Our certainty in the evidence included in this review is limited due to poor reporting and small sample sizes. Future studies should be well‐designed with adequate sample sizes and should be reported according to CONSORT (<a href="./references#CD014089-bbs2-0044" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [PMID: 20332509]">Schulz 2010</a>). The CONSORT extension to randomised cross‐over studies should be used when reporting cross‐over studies (<a href="./references#CD014089-bbs2-0019" title="DwanK , LiT , AltmanDG , ElbourneD . CONSORT 2010 statement: extension to randomised crossover trials. BMJ2019;366:l4378.">Dwan 2019</a>). Randomised controlled trials in people with primary Raynaud's phenomenon might be helpful to confirm these conclusions for that subset of Raynaud's phenomenon. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014089-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014089-sec-0008"></div> <div class="table" id="CD014089-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Raynaud's phenomenon (primary or secondary)<br/><b>Setting:</b> outpatient clinics<br/><b>Intervention:</b> phosphodiesterase 5 inhibitors (PDE5i) (tadalafil, sildenafil, vardenafil)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without PDE5i</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With PDE5i</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of attacks per week<br/>Follow‐up: range 4 weeks to 8 weeks<br/>Number of participants: 397 </p> <p>(8 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of attacks per week without PDE5i was 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of attacks per week with PDE5i was 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.07 lower<br/>(5.15 lower to 1.00 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may reduce the frequency of attacks of Raynaud's phenomenon by a small amount per week </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of attacks per day (minutes)<br/>Follow‐up: range 4 weeks to 8 weeks<br/>Number of participants: 397(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of attacks per day without PDE5i was 55 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of attacks per day with PDE5i was 50 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.31 minutes lower<br/>(8.90 lower to 1.71 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may result in a small reduction in the duration of Raynaud's phenomenon attacks per day </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of Raynaud's attack<br/>assessed with: 0 to 10 VAS; higher score means worse severity<br/>Follow‐up: mean 4 weeks </p> <p>Number of participants: 8</p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severity of Raynaud's attack without PDE5i was 3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean severity of Raynaud's attack with PDE5i was 1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.1 lower<br/>(2.7 lower to 1.4 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether PDE5i reduces the severity of an attack due to very low‐certainty evidence. </p> <p>Absolute difference: 20% better (14% better to 27% better)</p> <p>Relative per cent change: 57% better (38% better to 73% better)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity<br/>assessed with: 0 to 10 VAS; higher score means worse pain<br/>Follow‐up: range 4 weeks to 8 weeks </p> <p>Number of participants: 273</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain without PDE5i was 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean pain with PDE5i was 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.10<br/>(0.78 lower to 0.57 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may result in little to no difference in pain</p> <p>Absolute difference: 1% better (7.8% better to 5.7% worse)</p> <p>Relative per cent change: 3% better (26% better to 19% worse)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient global<br/>assessed with: 0 to 10 VAS; higher score means worse global assessment<br/>Follow‐up: mean 6 weeks </p> <p>Number of participants: 24</p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean patient global without PDE5i was 9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean patient global with PDE5i was 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.6 lower<br/>(4.45 lower to 2.73 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may improve the patient's global assessment of their disease</p> <p>Absolute difference: 36% better (27% better to 45% better)</p> <p>Relative per cent change: 39% better (30% better to 48% better)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> <p>Follow‐up: range 4 weeks to 8 weeks</p> <p>Number of participants: 411</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>See 'What happens' column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four studies reported no withdrawals due to adverse events. In five studies, the rate of withdrawals during treatment with PDE5i ranged from 2% to 20% compared with 2% to 4% in the placebo group. </p> <p>PDE5i probably increases slightly the likelihood of withdrawing from treatment due to an adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> <p>Follow‐up: range 4 weeks to 8 weeks</p> <p>Number of participants: 411</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>See 'What happens' column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seven studies reported no serious adverse events. The rate of serious adverse events ranged from 2% during treatment with PDE5i to 4% with placebo. </p> <p>PDE5i probably results in little or no difference in serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (few participants)<br/><sup>b</sup>Downgraded one level due to concerns about inconsistency (unexplained heterogeneity: I<sup>2</sup>≥ 69%)<br/><sup>c</sup> Downgraded two levels due to very serious concerns about imprecision<br/><sup>d</sup> Downgraded one level due to concerns about both risk of bias and publication bias (unpublished data from clinicaltrials.gov) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014089-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014089-sec-0009"></div> <section id="CD014089-sec-0010"> <h3 class="title" id="CD014089-sec-0010">Description of the condition</h3> <p>Raynaud's phenomenon is defined as vasospasms of the arteries or arterioles of the extremities, causing pallor and at least one other colour change upon reperfusion (restoring blood flow), such as cyanosis or redness (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>; <a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). Primary Raynaud's phenomenon is idiopathic and occurs in the absence of other underlying causes. Secondary Raynaud's phenomenon occurs in people with underlying diseases that affect the blood vessels, such as connective tissue diseases like scleroderma (also called systemic sclerosis) and lupus (<a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>); they are collectively referred to as 'systemic sclerosis spectrum disorders'. Raynaud's phenomenon may also be accompanied by digital ulcers, which can be secondary to ischaemia or the loss of blood to the digits (<a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). In the majority of cases (&gt; 80%), exposure to cold temperatures triggers this physiological response, but emotional stress has also been documented as another trigger (<a href="./references#CD014089-bbs2-0021" title="García-CarrascoM , Jiménez-HernándezM , EscárcegaRO , Mendoza-PintoC , Pardo-SantosR , LevyR . Treatment of Raynaud's phenomenon. Autoimmunity Reviews2008;8(1):62-8.">García‐Carrasco 2008</a>; <a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). Primary Raynaud's phenomenon has an earlier onset (median age of onset is around 14 years of age) and the symptoms are milder. Secondary Raynaud's phenomenon has a later onset (usually after 40 years of age), with more severe symptoms, and may be associated with complications such as tissue loss, ulcers, and amputations (<a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). People whose Raynaud's phenomenon is secondary to systemic sclerosis spectrum disorders often develop irreversible digital ischaemias (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). Scleroderma is characterised by fibrosis of the skin and internal organs, including the gastrointestinal tract, lungs, kidney, and heart (<a href="./references#CD014089-bbs2-0040" title="OrtonneJP , TorzuoliC , DujardinP , FraitagB . Ketanserin in the treatment of systemic sclerosis: a double‐blind controlled trial. British Journal of Dermatology1989;120(2):261-6.">Ortonne 1989</a>) </p> <p>The prevalence of Raynaud's phenomenon is geographically variable based on climate conditions, but has been estimated at around 3% to 5% in the general population (<a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). The majority of cases (80% to 90%) are primary Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). Secondary Raynaud's phenomenon accounts for 10% to 20% of the prevalence, depending on the underlying cause. It is estimated that over 90% of people with scleroderma have Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0036" title="LevienTL . Advances in the treatment of Raynaud's phenomenon. Vascular Health and Risk Management2010;24(6):167-77.">Levien 2010</a>; <a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). In general, Raynaud's phenomenon is much more common in women: the prevalence is 2% to 20% in women compared to 1% to 12% in men (<a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). Primary Raynaud's phenomenon has a genetic component: approximately 50% of people with primary Raynaud's phenomenon have a first‐degree relative with the disease (<a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). Diagnosis of primary Raynaud's phenomenon is based on patient history (i.e. sensitivity to cold exposure presenting as pallor of the fingers and toes, often followed by rubor or cyanosis) and a complete evaluation to rule out the presence of underlying causes. Diagnosis of secondary Raynaud's phenomenon includes an older age of onset (i.e. &gt; 40 years), often with more severe symptoms, and positive laboratory tests suggesting an underlying connective tissue disease (i.e. positive antinuclear antibodies, positive rheumatoid factor, and the presence of specific autoantibodies), and microscopy of the nail folds indicating the presence of a microvascular disease (<a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). </p> <p>The pathogenesis of Raynaud's phenomenon is not clearly understood, but a general hypothesis is that the major underlying cause is an imbalance of vasoconstrictors and vasodilators, with a higher prevalence of vasoconstrictors (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). Evidence suggests that causes of the underlying pathogenesis of Raynaud's phenomenon likely include abnormalities in the blood vessels (i.e. smooth muscle and endothelium), abnormalities in the neural control of vascular tone, and abnormalities in intravascular mediators, including those produced by platelet activation and oxidative stress (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). However, vascular abnormalities may be minimal in primary Raynaud's phenomenon and more severe in secondary Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>; <a href="./references#CD014089-bbs2-0046" title="WigleyFM . Raynaud's Phenomenon. New England Journal of Medicine2002;347(13):1001-8.">Wigley 2002</a>). This might explain why Raynaud's phenomenon secondary to systemic sclerosis spectrum disorders but not primary Raynaud's phenomenon, often leads to irreversible digital ischaemias and is much more severe (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). In addition, secondary Raynaud's phenomenon is often associated with structural abnormalities in the microvascular system and arteries, which are apparent upon evaluation. Since Raynaud's phenomenon is more common in women, some have hypothesised that hormonal factors may also be involved (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). It has been estimated that 14% to 37% of primary Raynaud's phenomenon eventually progresses to secondary Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0038" title="MaundrellA , ProudmanSM . Epidemiology of Raynaud’s phenomenon. In: Raynaud's Phenomenon. 1st edition. New York (NY): Springer, 2015:21-35.">Maundrell 2015</a>). </p> <p>For the majority of Raynaud's phenomenon (which is primary Raynaud's phenomenon), treatment is conservative (i.e. avoiding cold temperatures and emotional stress). However, for secondary Raynaud's phenomenon, a pharmacological intervention is required and many different drugs that may be beneficial are available (<a href="./references#CD014089-bbs2-0021" title="García-CarrascoM , Jiménez-HernándezM , EscárcegaRO , Mendoza-PintoC , Pardo-SantosR , LevyR . Treatment of Raynaud's phenomenon. Autoimmunity Reviews2008;8(1):62-8.">García‐Carrasco 2008</a>; <a href="./references#CD014089-bbs2-0022" title="GoundryB , BellL , LangtreeM , MoorthyA . Diagnosis and management of Raynaud’s phenomenon. BMJ2012;344:e289.">Goundry 2012</a>; <a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). </p> </section> <section id="CD014089-sec-0011"> <h3 class="title" id="CD014089-sec-0011">Description of the intervention</h3> <p>Due to the multiple mechanisms that are thought to be involved in Raynaud's phenomenon pathogenesis, many different drug treatments have been used over the past two decades. Older medications used to treat Raynaud's phenomenon, such as ganglion blockers and alpha blockers, had many side effects, such as postural hypotension and dry mouth (<a href="./references#CD014089-bbs2-0025" title="HansteenV . Medical treatment in Raynaud's disease. Acta Chirurgica Scandinavica. Supplementum1976;465:87-91.">Hansteen 1976</a>). Newer medications cause fewer side effects and include: drugs that inhibit vasoconstriction (i.e. calcium channel blockers (<a href="./references#CD014089-bbs2-0042" title="RirashF , TingleyPC , HardingSE , MaxwellLJ , GhogomuET , WellsGA , et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD000467. [DOI: 10.1002/14651858.CD000467.pub2]">Rirash 2017</a>), angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, serotonin reuptake inhibitors, and selective alpha‐2‐adrenoceptor blockers); those that enhance vasodilation (i.e. prostanoids, calcitonin gene‐related peptide blockers, and phosphodiesterase 5 inhibitors); drugs that reduce endothelial injury (i.e. prostanoids and endothelin‐1‐receptor antagonists); and drugs that inhibit platelet activation or pro‐coagulation activities (i.e. antiplatelets and antifibrinolytics) (<a href="./references#CD014089-bbs2-0021" title="García-CarrascoM , Jiménez-HernándezM , EscárcegaRO , Mendoza-PintoC , Pardo-SantosR , LevyR . Treatment of Raynaud's phenomenon. Autoimmunity Reviews2008;8(1):62-8.">García‐Carrasco 2008</a>; <a href="./references#CD014089-bbs2-0022" title="GoundryB , BellL , LangtreeM , MoorthyA . Diagnosis and management of Raynaud’s phenomenon. BMJ2012;344:e289.">Goundry 2012</a>; <a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). Some drug classes, such as the angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers, act through several of these mechanisms (<a href="./references#CD014089-bbs2-0026" title="HerrickAL . Pathogenesis of Raynaud's phenomenon. Rheumatology2005;44(5):587-96.">Herrick 2005</a>). For this review, the drug class of interest is phosphodiesterase 5 inhibitors (PDE5i). PDE5i increase vasodilation, allowing for improved blood flow (<a href="./references#CD014089-bbs2-0031" title="ImpensAJ , PhillipsK , SchiopuE . PDE5i in scleroderma Raynaud phenomenon and digital ulcers: current status of clinical trials. International Journal of Rheumatology2011;2011:392542.">Impens 2011</a>). Initially indicated for the treatment of erectile dysfunction, PDE5i have recently become important alternatives for the management of Raynaud’s phenomenon secondary to systemic sclerosis spectrum disorders (<a href="./references#CD014089-bbs2-0032" title="Kowal-BieleckaO , FransenJ , AvouacJ , BeckerM , KulakA , AllanoreY , et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of Rheumatic Diseases2017;76(8):1327-39. [PMID: PMID: 27941129]">Kowal‐Bielecka 2017</a>). </p> </section> <section id="CD014089-sec-0012"> <h3 class="title" id="CD014089-sec-0012">How the intervention might work</h3> <p>Nitric oxide facilitates the breakdown of guanosine monophosphate (GMP) into cyclic GMP (cGMP), which then accumulates inside of cells and leads to vasodilation and platelet activation (<a href="./references#CD014089-bbs2-0036" title="LevienTL . Advances in the treatment of Raynaud's phenomenon. Vascular Health and Risk Management2010;24(6):167-77.">Levien 2010</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>). PDE5i are a class of enzymes that catalyse the breakdown of cGMP, which then ends the cycle of smooth muscle cell relaxation and vasodilation. PDE5i, including sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis), inhibit the normal activity of phosphodiesterase 5 enzymes and prolong vasodilation and blood flow to the extremities (<a href="./references#CD014089-bbs2-0031" title="ImpensAJ , PhillipsK , SchiopuE . PDE5i in scleroderma Raynaud phenomenon and digital ulcers: current status of clinical trials. International Journal of Rheumatology2011;2011:392542.">Impens 2011</a>). Hence, rheumatologists began the off‐label use of phosphodiesterase 5 inhibitors to address the symptoms of Raynaud's phenomenon (particularly the more severe secondary Raynaud's phenomenon) which may be unresponsive to other treatments (<a href="./references#CD014089-bbs2-0036" title="LevienTL . Advances in the treatment of Raynaud's phenomenon. Vascular Health and Risk Management2010;24(6):167-77.">Levien 2010</a>). These three drugs are similar in their pharmacokinetics. </p> </section> <section id="CD014089-sec-0013"> <h3 class="title" id="CD014089-sec-0013">Why it is important to do this review</h3> <p>Several randomised controlled trials (RCTs) have been conducted for the treatment of idiopathic or primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis spectrum disorders. In fact, a systematic review and meta‐analysis concluded that PDE5i have a moderate effect on secondary Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a>). Thus, recommendations set forth by the European Society for Vascular Medicine and the European League against Rheumatism suggest that, amongst other pharmacologic agents, PDE5i are useful options in the management of Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0018" title="BelchJ , CarlizzaA , CarpentierPH , ConstansJ , KhanF , WautrechtJC , et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. VASA - European Journal of Vascular Medicine2017;46(6):413-23. [DOI: 10.1024/0301-1526/a000661] [PMID: 28895508]">Belch 2017</a>; <a href="./references#CD014089-bbs2-0032" title="Kowal-BieleckaO , FransenJ , AvouacJ , BeckerM , KulakA , AllanoreY , et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of Rheumatic Diseases2017;76(8):1327-39. [PMID: PMID: 27941129]">Kowal‐Bielecka 2017</a>). However, an updated systematic review of the literature is needed to more clearly establish the role of PDE5i in the management of Raynaud's phenomenon and aid clinicians with decisions about treatment options for their patients. The objective of this review was to investigate the benefits and harms of PDE5i compared to placebo for the treatment of Raynaud's phenomenon. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014089-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014089-sec-0014"></div> <p>To assess the benefits and harms of phosphodiesterase 5 inhibitors (PDE5i) compared to placebo for the treatment of Raynaud's phenomenon. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014089-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014089-sec-0015"></div> <section id="CD014089-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014089-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs), with a minimum duration of one week. We included studies reported as full‐text, those published as abstract only, and unpublished data reported on trial registries. We imposed no language restriction. We included both cross‐over and parallel studies. </p> </section> <section id="CD014089-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of adults aged 18 years and over with a diagnosis of primary Raynaud's phenomenon or Raynaud's phenomenon secondary to systemic sclerosis or other connective tissue diseases, as defined by a physician (<a href="./references#CD014089-bbs2-0035" title="LeRoyEC , MedsgerTA . Raynaud's phenomenon: a prosposal for classification. Clinical and Experimental Rheumatology1992;10:485-8.">LeRoy 1992</a>; <a href="./references#CD014089-bbs2-0034" title="LeRoyEC , BlackC , FleischmajerR , JablonskaS , KriegT , Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. Journal of Rheumatology1988;15(2):202-5. [PMID: 3361530]">LeRoy 1988</a>; <a href="./references#CD014089-bbs2-0037" title="MasiAT , RodnanGP , Medsger TA Jr. ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis and Rheumatism1980;23(5):581-90.">Masi 1980</a>). We placed no restriction on the subset or stage of disease. In the absence of an accepted definition for Raynaud's phenomenon, we included all participants reported to have Raynaud's phenomenon and noted the criteria that study authors used to define Raynaud's phenomenon. </p> </section> <section id="CD014089-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included phosphodiesterase 5 inhibitors (PDE5i) at any dose versus placebo. PDE5i currently available include sildenafil, tadalafil, vardenafil, and avanafil. We also considered new PDE5i in the development phase (i.e. not yet having regulatory approval) as eligible for inclusion. </p> </section> <section id="CD014089-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014089-sec-0021"> <h5 class="title">Major outcomes</h5> <p> <ul id="CD014089-list-0001"> <li> <p>Frequency of attacks (average number of attacks per week or change in frequency per week) </p> </li> <li> <p>Duration of attacks (average duration per attack, in minutes)</p> </li> <li> <p>Severity of attacks (converted to a common scale, such as the 10 cm visual analogue scale (VAS) </p> </li> <li> <p>Pain (intensity of pain during attacks)</p> </li> <li> <p>Patient global assessment (self‐reported assessment of disability due to Raynaud's phenomenon) </p> </li> <li> <p>Withdrawals (any withdrawals due to adverse effects)</p> </li> <li> <p>Serious adverse events (adverse effects requiring withdrawal from study, hospitalisations, or death) </p> </li> </ul> </p> </section> <section id="CD014089-sec-0022"> <h5 class="title">Minor outcomes</h5> <p> <ul id="CD014089-list-0002"> <li> <p>Function (measure of how Raynaud's phenomenon affects the daily functioning of the individual) </p> </li> <li> <p>Raynaud's condition score (RCS), a validated assessment of Raynaud's severity based on the daily frequency, duration, and severity of attacks (<a href="./references#CD014089-bbs2-0039" title="MerkelPA , HerlynK , MartinRW , AndersonJJ , MayesMD , BellP , et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism2002;46(9):2410-20.">Merkel 2002</a>) </p> </li> <li> <p>Physician's global assessment (physician‐assessed measure of disability due to Raynaud's phenomenon) </p> </li> <li> <p>Change in digital ulceration (any changes whether positive (i.e. healing, improvement) or negative (i.e. worsening of existing ulcers or new ulcers) </p> </li> <li> <p>Treatment preference</p> </li> <li> <p>General improvement (a measure of self‐reported overall improvement of Raynaud's condition)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </section> </section> </section> <section id="CD014089-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014089-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We designed a sensitive search strategy to retrieve RCTs from the following electronic bibliographic databases: </p> <p> <ul id="CD014089-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (searched 23 June 2022); </p> </li> <li> <p>MEDLINE via Ovid (1946 to 23 June 2022);</p> </li> <li> <p>Embase via Ovid (1947 to 23 June 2022).</p> </li> </ul> </p> <p>We did not apply any language restrictions. We used the randomised controlled trials filter from Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014089-bbs2-0033" title="LefebvreC , ManheimerM , GlanvilleJ , on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Lefebvre 2017</a>)<i>.</i> We devised the search strategy for the Ovid MEDLINE interface and then adapted it for use with the other databases. The search strategies are available in <a href="./appendices#CD014089-sec-0107">Appendix 1</a>. This review is one in a suite of reviews of interventions for Raynaud's Phenomenon. This search is designed to find all RCTs in Raynaud's Phenomenon and then map the results to the specific interventions of interest. </p> </section> <section id="CD014089-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched:</p> <p> <ul id="CD014089-list-0004"> <li> <p>World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch; searched 23 June 2022); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov; searched 23 June 2022). </p> </li> </ul> </p> <p>For safety assessments, we searched the websites of the following regulatory agencies using the keywords "phosphodiesterase 5 inhibitors, tadalafil, Cialis, vardenafil, Levitra, sildenafil, and Viagra". </p> <p> <ul id="CD014089-list-0005"> <li> <p>US Food and Drug Administration‐MedWatch (www.fda.gov/Safety/MedWatch/default.htm; 23 June 2022); </p> </li> <li> <p>European Medicines Evaluation Agency (www.ema.europa.eu; 23 June 2022);</p> </li> <li> <p>Australian Adverse Drug Reactions Bulletin (www.tga.gov.au/safety/ews‐monitoring.htm; 23 June 2022); </p> </li> <li> <p>UK Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance and drug safety updates (www.mhra.gov.uk/Safetyinformation/index.htm; 23 June 2022). </p> </li> </ul> </p> <p>We hand‐searched the list of references from primary citations. We also searched for errata or retractions from included studies published in full‐text form. </p> <p>We contacted the authors of studies when study data were missing.</p> </section> </section> <section id="CD014089-sec-0026"> <h3 class="title" id="CD014089-sec-0026">Data collection and analysis</h3> <p>This review is one of a suite of reviews of drug interventions for Raynaud’s Phenomenon. In order to collect data on the same outcomes of interest and to facilitate easy comparison of reviews, we published a generic Cochrane protocol, 'Drug interventions versus placebo for the treatment of Raynaud’s phenomenon: generic protocol' (<a href="./references#CD014089-bbs2-0047" title="RirashF , TingeyPC , HardingSE , MaxwellLJ , GhogomuET , MaltezN , et al. Drug interventions versus placebo for the treatment of Raynaud’s phenomenon: generic protocol. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD011813. [DOI: 10.1002/14651858.CD011813.pub2]">Rirash 2021</a>). This review follows the methods outlined in that protocol. </p> <section id="CD014089-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (PCT, SEH, FR or LJM) independently reviewed the titles and abstracts retrieved from the search strategy. We excluded those that clearly did not meet the inclusion criteria. For the rest, we obtain the full‐text articles and two review authors independently determined whether they met the inclusion criteria and documented the reasons for exclusion. We organized the references by study and collated multiple reports of the study under one primary reference. We did not use the outcomes reported to determine study eligibility. We resolved differences regarding selection by consulting a third review author (JP). We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD014089-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD014089-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram; CT=clinicaltrials.gov; ICTRP=International Clinical Trials Registry Platform" data-id="CD014089-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram; CT=clinicaltrials.gov; ICTRP=International Clinical Trials Registry Platform </p> </div> </div> </div> </section> <section id="CD014089-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We recorded study characteristics and outcome data on a data collection form that we had piloted on at least one study in the review. One review author (FR) extracted study characteristics from included studies, and a second review author (LJM or NM) spot‐checked study characteristics for accuracy against the study report. We extracted the following study characteristics. </p> <p> <ul id="CD014089-list-0006"> <li> <p><b>Methods</b>: study design, duration, details of any "run‐in" period, washout period, number of centres and locations, setting, withdrawals, and date of study. </p> </li> <li> <p><b>Participants</b>: number, mean age, age range, sex, disease duration, severity of condition, diagnostic criteria, and inclusion and exclusion criteria. </p> </li> <li> <p><b>Interventions</b>: intervention, comparison, concomitant medications, and excluded medications. </p> </li> <li> <p><b>Outcomes</b>: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p><b>Characteristics of study design</b>: as outlined below in the <a href="#CD014089-sec-0029">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p><b>Notes</b>: funding for study and notable declarations of interest of study authors. </p> </li> </ul> </p> <p>Two review authors (NM, LJM or FR) independently extracted outcome data from included studies. We sought the opinion of a third review author (JP) to resolve any disagreements. For parallel‐group studies, we extracted the number of events and the number of participants per group for dichotomous outcomes. For continuous outcomes, we extracted means, standard deviations (SD), and number of participants per group. We converted the SD to a standard error (SE) for entry into the generic inverse variance method in <a href="./references#CD014089-bbs2-0041" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a> using the formula in Chapter 6 of the Cochrane Handbook (<a href="./references#CD014089-bbs2-0030" title="HigginsJPT , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). For cross‐over studies, we extracted the mean difference (MD) and SE of the MD, if it was available in the study. Where the SE was not reported, we imputed the SE of the mean MD using the approaches outlined in Chapter 23.2 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD014089-bbs2-0029" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook/.">Higgins 2020</a>). When 95% confidence intervals (CI) were reported (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>), we converted those to SE using the formula SE = (upper limit ‐ lower limit)/3.92. When medians and interquartile ranges (IQR) were reported (<a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>), we assumed the mean for the median and converted the IQR to SD using the formula, SD = IQR/1.35. For adverse events, we extracted the data for events not attributable to the medication if both attributed and non‐attributed data were reported in an included study. </p> <p>We noted in the <a href="./references#CD014089-sec-0117" title="">Characteristics of included studies</a> if outcome data were not reported in a usable way, and when data were transformed or estimated from a graph. We resolved disagreements by consensus or by consultation with a third review author (JP or GAW). One review author (FR, NM or LJM) transferred data into <a href="./references#CD014089-bbs2-0041" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>. We double‐checked that data were entered correctly by comparing data presented in the systematic review against data in the study reports. </p> <p>For all outcomes, we extracted data from studies and reported as follows.</p> <p>‐ If both final values and change from baseline values were reported for the same outcome, we preferentially extracted changes from baseline. </p> <p>‐ If both unadjusted and adjusted values were reported for the same outcome, we extracted the adjusted values. </p> <p>‐ If data were analysed based on intention‐to‐treat (ITT) and another sample (i.e. per‐protocol, as‐treated), we extracted both but noted these differences. </p> <p>‐ If data were available for multiple time points, we used the data that corresponded most closely with those of other RCTs. </p> </section> <section id="CD014089-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NM, LJM) independently assessed the risk of bias of each included study according to the domain‐based evaluation outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014089-bbs2-0028" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cohrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>)<i>.</i> We compared assessments, identified any inconsistencies, and established consensus. </p> <p>We rated the following domains for each included study as low risk, high risk, or unclear risk of bias. </p> <section id="CD014089-sec-0030"> <h5 class="title">(1) Random sequence generation: checking for possible selection bias</h5> <p>For each included study, we described the methods used to generate the allocation sequence in sufficient detail to allow for assessment of whether comparable groups will be produced by the study. The methods were assessed as follows. </p> <p> <ul id="CD014089-list-0007"> <li> <p>Low risk of bias (truly randomised methods were used (i.e. random number table, computer‐generated randomisation)). </p> </li> <li> <p>High risk of bias (processes that are vulnerable to manipulation such as hospital admission date, alternate assignment, etc.). </p> </li> <li> <p>Unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0031"> <h5 class="title">(2) Allocation concealment: checking for possible selection bias</h5> <p>For each included study, we described the methods used to conceal the allocation to intervention prior to assignment, and whether concealment could have been broken during any stage of the study. The methods were assessed as follows. </p> <p> <ul id="CD014089-list-0008"> <li> <p>Low risk of bias (i.e. telephone or central randomisation, consecutively‐numbered, sealed, opaque envelopes). </p> </li> <li> <p>High risk of bias (processes that are vulnerable to manipulation such as unsealed envelopes, alternate assignment). </p> </li> <li> <p>Unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0032"> <h5 class="title">(3.1) Blinding of participants and personnel: checking for possible performance bias</h5> <p>For each included study, we described the methods (if any) used to blind participants and personnel from knowing participants' intervention allocation. The methods were assessed as follows. </p> <p> <ul id="CD014089-list-0009"> <li> <p>Low, high, or unclear risk of bias for participants.</p> </li> <li> <p>Low, high, or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0033"> <h5 class="title">(3.2) Blinding of outcome assessment: checking for possible detection bias</h5> <p>For each included study, we described the methods (if any) used to blind outcome assessors from knowing participants' intervention allocation. The methods used for blinding were assessed as follows. </p> <p> <ul id="CD014089-list-0010"> <li> <p>Low, high, or unclear risk of bias for assessors.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0034"> <h5 class="title">(4) Incomplete outcome data: checking for possible bias due to attrition and methods used to handle missing outcome data </h5> <p>For each included study and for each outcome, we assessed for completeness of data (i.e. attrition, exclusions, and number included in analysis compared to the number of participants that were randomised, whether missing data and dropouts were balanced between groups for each outcome). The methods used were assessed as follows. </p> <p> <ul id="CD014089-list-0011"> <li> <p>Low risk of bias (no missing outcome data, missing outcome data balanced for groups).</p> </li> <li> <p>High risk of bias (reasons for or numbers of missing data unbalanced across groups or violation of intention‐to‐treat protocol). </p> </li> <li> <p>Unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0035"> <h5 class="title">(5) Selective outcome reporting: checking for possible reporting bias</h5> <p>For each included study and for each outcome, we assessed for selective outcome reporting by checking pre‐specified outcomes in the methods of each study against those reported in the results. Selective outcome reporting was assessed as follows. </p> <p> <ul id="CD014089-list-0012"> <li> <p>Low risk of bias (all pre‐specified outcomes of interest were reported).</p> </li> <li> <p>High risk of bias (all pre‐specified outcomes of interest were not reported, outcomes of interest were not reported completely, one or more primary outcomes reported were not pre‐specified). </p> </li> <li> <p>Unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0036"> <h5 class="title">(6) Other bias: checking for bias not covered through 1 to 5 above</h5> <p>We assessed each included study for other concerns that may lead to a risk of bias, including similarity of baseline characteristics for parallel studies. For cross‐over studies, we considered the following questions in our assessment. </p> <p> <ul id="CD014089-list-0013"> <li> <p>Was use of a cross‐over design appropriate?</p> </li> <li> <p>Is it clear that the order of receiving treatments was randomised?</p> </li> <li> <p>Can it be assumed that the study was not biased from carryover effects?</p> </li> <li> <p>Are unbiased data available?</p> </li> </ul> </p> <p>This domain was assessed as follows.</p> <p> <ul id="CD014089-list-0014"> <li> <p>Low risk of other bias.</p> </li> <li> <p>High risk of other bias.</p> </li> <li> <p>Unclear risk of other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear risk, and provided a quote from the study report together with a justification for our judgement in the risk of bias table (see <a href="https://archie.cochrane.org/sections/documents/view?document=E602372382E26AA200C24AE7CDF196B9&amp;format=JATS#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table). </p> </section> </section> <section id="CD014089-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We estimated the treatment effect for continuous outcomes using the MD and for dichotomous outcomes using risk ratios (RR), with 95% CIs reported with each outcome estimate. In the case of rare events (&lt; 10%), we reported the Peto odds ratio (OR). We also calculated absolute risk differences and relative per cent changes for the major outcomes. </p> </section> <section id="CD014089-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>AThe unit of analysis for each outcome was the participant, except for digital ulcers where the unit of analysis was the digital ulcer (since the total number of participants with digital ulcers is not always reported). We consulted with a statistician to ensure that data were correctly reported when the unit of analysis was the digital ulcer. We did not pool these data but instead reported them narratively. </p> <p>We planned that when multiple arms were reported in a single study, we would include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we would halve the control group to avoid double‐counting. </p> <p>We assessed cross‐over studies to determine if it was likely that there was a problem with a carryover effect, taking into consideration the type of intervention and the length of the washout period. If we deemed this a concern, then we planned to include only first‐phase data from cross‐over studies. When data from both periods of the cross‐over study were available, we followed the methods described in Chapter 16.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?document=z1505282108566449067483580429377&amp;format=JATS#REF-Higgins-2011a" target="_blank">Higgins 2011a</a>). We consulted with a statistician (GAW) to ensure the analysis was performed correctly. </p> </section> <section id="CD014089-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We made all possible efforts to obtain any missing data. When possible, we estimated missing SDs using other available data, such as standard errors, P values, CIs, error bars in graphs, range, and sample size. </p> </section> <section id="CD014089-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the Chi<sup>2</sup> test and I<sup>2</sup> statistic.We considered a Chi<sup>2</sup> testwith a P value of less than 0.1 and I<sup>2</sup> of greater than 50% to be significant (<a href="./references#CD014089-bbs2-0027" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>; <a href="./references#CD014089-bbs2-0028" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cohrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We also inspected forest plots visually for outliers. </p> </section> <section id="CD014089-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates of this review, where outcomes include at least 10 studies, we will assess publication bias with funnel plots (<a href="./references#CD014089-bbs2-0020" title="EggerM , Zellweger-ZahnerT , ScheiderM , JunkerC , LengelerAG . Language bias in randomised controlled trials published in English and German. Lancet1997;350(907):326-9.">Egger 1997</a>). </p> </section> <section id="CD014089-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Using Cochrane's statistical software, <a href="./references#CD014089-bbs2-0041" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>, we conducted a meta‐analysis using the generic inverse variance method and the random‐effects model, when we decided that outcomes were clinically similar. We used the fixed‐effect model when only one study was in the forest plot. We restricted the primary analysis for the major outcomes to those studies that were at a low or unclear risk of selection and detection bias. We decided to pool the studies marked as 'unclear' risk of bias with those marked as 'low' risk of bias because we judged that 'unclear' studies lacked detailed reporting of methods, and that they probably used adequate methodology. </p> </section> <section id="CD014089-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed the following subgroup analyses for the major outcomes frequency and duration of attacks. </p> <p> <ul id="CD014089-list-0015"> <li> <p>Raynaud's phenomenon type (primary or secondary)</p> </li> <li> <p>Type of phosphodiesterase‐5 inhibitor</p> </li> <li> <p>Sildenafil dosing regime (the other drugs used the same dosing regime)</p> </li> </ul> </p> <p>We did not perform the planned subgroup analysis by route of treatment administration (i.e. oral, intravenous, ointment) as all included interventions used the same route of administration. </p> <p>In addition, we performed a post hoc subgroup analysis by RCT type (cross‐over compared to parallel) to assess whether there was a differential effect evident across the different study designs. </p> <p>We used the formal test for subgroup interactions in <a href="./references#CD014089-bbs2-0041" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a> and used caution in the interpretation of subgroup analyses. We compared the magnitude of the effects between the subgroups by assessing the overlap of the CIs of the summary estimates. Non‐overlap of the CIs indicates statistical significance. </p> </section> <section id="CD014089-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses to explore the robustness of the results of the major outcomes, stratified by the following factors when there were sufficient data. </p> <p> <ul id="CD014089-list-0016"> <li> <p>Study quality: all studies pooled together regardless of risk of bias.</p> </li> <li> <p>Study duration: less than eight weeks compared to all time points.</p> </li> <li> <p>Diagnostic inclusion criteria used in the study.</p> </li> <li> <p>Time of the year study was performed.</p> </li> <li> <p>Estimations or imputations of standard deviations or correlation coefficients from cross‐over studies. </p> </li> </ul> </p> <p>We interpreted results from these exploratory analyses with caution.</p> </section> <section id="CD014089-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD014089-sec-0046"> <h5 class="title">Grading the evidence</h5> <p>We used the GRADE approach for evaluating the overall certainty of evidence for reported outcomes (<a href="./references#CD014089-bbs2-0023" title="Grading Working Group. Grading quality of evidence and strength of recommendations. BMJ2008;336(7653):1106-10.">GRADE 2008</a>). Based on the GRADE approach, we evaluated the certainty of the evidence as follows. </p> <p> <ul id="CD014089-list-0017"> <li> <p>High certainty from RCTs or from double upgrade observational studies.</p> </li> <li> <p>Moderate certainty from evidence that is downgraded by one level due to a study limitation.</p> </li> <li> <p>Low certainty from evidence that is double downgraded for study limitations.</p> </li> <li> <p>Very low certaint<i>y</i> from evidence that is triple downgraded due to multiple study limitations. </p> </li> </ul> </p> <p>We downgraded the certainty of the evidence based on the following factors, as specified by the GRADE approach. </p> <p> <ul id="CD014089-list-0018"> <li> <p>Limitations in the design and implementation of available studies suggesting high likelihood of bias. </p> </li> <li> <p>Indirectness of evidence (indirect population, intervention, control, outcomes).</p> </li> <li> <p>Unexplained heterogeneity or inconsistency of results.</p> </li> <li> <p>Imprecision of results (wide CIs from small sample size).</p> </li> <li> <p>High probability of publication bias.</p> </li> </ul> </p> </section> <section id="CD014089-sec-0047"> <h5 class="title">Summary of findings table</h5> <p>We used the methods and recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to grade the certainty of the evidence (<a href="./references#CD014089-bbs2-0045" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Available from: www.training.cochrane.org/handbook.">Schünemann 2017</a>). We used <a href="./references#CD014089-bbs2-0024" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 1 September 2021. Available at gradepro.org.">GRADEpro GDT</a> to present the summary of findings table in Review Manager. For continuous outcomes, we calculated the absolute per cent change by dividing the MD by the number of points on the scale and converting to a percentage. We presented this result in the 'What happens' column. We calculated the relative per cent change as the absolute benefit (MD) divided by the baseline mean of the control group, and expressed as a percentage. We presented the following seven major outcomes of this review in the summary of findings table: </p> <p> <ul id="CD014089-list-0019"> <li> <p>frequency of attacks (average attacks per week or change in frequency per week);</p> </li> <li> <p>duration of attacks (average duration per attack in minutes);</p> </li> <li> <p>severity of attacks (converted to a common scale such as the 10 cm visual analogue scale); </p> </li> <li> <p>pain (intensity of pain during attacks);</p> </li> <li> <p>patient global assessment (self‐reported assessment of disability due to Raynaud's phenomenon); </p> </li> <li> <p>withdrawals (any withdrawals due to adverse effects);</p> </li> <li> <p>serious adverse events (adverse effects requiring withdrawal from study, hospitalisations, or death). </p> </li> </ul> </p> <p>The <a href="./full#CD014089-tbl-0001">summary of findings Table 1</a> table contains the intervention effect estimates, comparators, and an assessment of the certainty of the evidence using GRADE. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014089-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014089-sec-0048"></div> <section id="CD014089-sec-0049"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD014089-sec-0117" title="">Characteristics of included studies</a>, <a href="./references#CD014089-sec-0118" title="">Characteristics of excluded studies</a>, and <a href="./references#CD014089-sec-0119" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD014089-sec-0050"> <h4 class="title">Results of the search</h4> <p>The search of CENTRAL, MEDLINE and Embase resulted in 5127 records. Five additional records were identified through hand searching and trial registry searches. After de‐duplication, 3546 records were screened and 33 full‐text records specific to PDE5i were assessed. After examining the full texts, we excluded 10 full‐text records linked to 5 studies and put 3 studies (4 records) in awaiting classification. Nine trials linked to 19 records were included. </p> <p><a href="#CD014089-fig-0001">Figure 1</a> shows further details on the results of the search. </p> <p>The search of regulatory websites found special warnings on the drug labels from the European Medicines Agency and the US Food and Drug Administration websites. Details are reported in the main results. </p> </section> <section id="CD014089-sec-0051"> <h4 class="title">Included studies</h4> <p>Nine studies comparing PDE5i to a placebo for the treatment of Raynaud's phenomenon or Raynaud's phenomenon secondary to systemic sclerosis met our inclusion criteria (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). These are described in detail in the <a href="./references#CD014089-sec-0117" title="">Characteristics of included studies</a> table. </p> <section id="CD014089-sec-0052"> <h5 class="title">Study design</h5> <p>Six studies used a cross‐over design (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). Three were parallel RCTs (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>). </p> </section> <section id="CD014089-sec-0053"> <h5 class="title">Study setting</h5> <p>Two studies were performed in India (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>), two were performed in Germany (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>), and one in Brazil (<a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>). Four studies did not report location (<a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>). The studies ranged in duration from four to eight weeks. </p> </section> <section id="CD014089-sec-0054"> <h5 class="title">Study size</h5> <p>The number of participants in the studies ranged from 10 to 122. In total, there were 411 randomised participants. </p> </section> <section id="CD014089-sec-0055"> <h5 class="title">Participants</h5> <p>Participants were predominantly female in all nine included studies. Participants with Raynaud's phenomenon secondary to systemic sclerosis fulfilled the American College of Rheumatology criteria in five studies (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a> applied the classification criteria for participant selection as per <a href="./references#CD014089-bbs2-0035" title="LeRoyEC , MedsgerTA . Raynaud's phenomenon: a prosposal for classification. Clinical and Experimental Rheumatology1992;10:485-8.">LeRoy 1992</a>. Three studies did not specify classification criteria (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>). Two studies also included a small proportion (approximately 12%) of people with primary Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>). <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a> had separate study arms for primary and secondary Raynaud's phenomenon. <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a> did not report proportion or Raynaud's phenomenon subtype. </p> </section> <section id="CD014089-sec-0056"> <h5 class="title">Interventions</h5> <p>Four studies used 20 mg of tadalafil (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). Three studies used sildenafil in doses ranging from 100 mg to 200 mg per day (<a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>). One cross‐over study used 20 mg of vardenafil per day and reported a significant carryover effect (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>). One study used 20 mg per day of PF‐00489791 (<a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>). </p> </section> <section id="CD014089-sec-0057"> <h5 class="title">Outcomes</h5> <p>Primary outcomes in the majority of studies pertained to attacks of Raynaud’s phenomenon (Raynaud's condition score (RCS), frequency, and duration of attacks) (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The primary outcome in <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a> was defined as change in blood flow as measured by laser Doppler after cold stimulus. The focus of <a href="./references#CD014089-bbs2-0011" title="FriedmanEA , HarrisPA , WoodAJ , SteinCM , KurnikD . The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clinical Pharmacology and Therapeutics2007;81(4):503-9. ">Friedman 2007</a> was vasoconstriction of blood vessels and reported skin blood flow and temperature parameters which were not outcomes of interest in this review. Secondary outcomes included characteristics of digital ulcers, patient and physician global assessments, digital blood pressure, capillary diameter, serum levels of biomarkers, quality of life, and function indices. </p> </section> </section> <section id="CD014089-sec-0058"> <h4 class="title">Excluded studies</h4> <p>After examining the 33 full‐text records, we excluded ten records linked to five trials and put four records linked to 3 studies in awaiting classification. Of the excluded studies, two were an ineligible study design (<a href="./references#CD014089-bbs2-0011" title="FriedmanEA , HarrisPA , WoodAJ , SteinCM , KurnikD . The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clinical Pharmacology and Therapeutics2007;81(4):503-9. ">Friedman 2007</a> ‐a single dose followed by a heating/cooling procedure to measure skin blood flow and <a href="./references#CD014089-bbs2-0013" title="CracowskiJL , RoustitM , MouhibM , LotitoA , KhouriC , Giai J et al. On demand sildenafl as a treatment of raynaud's phenomenon: A series of N-of-1 trials. In: 2nd Joint Meeting of the European Society for Microcirculation, ESM and European Vascular Biology Organisation and EVBO. Geneva Switzerland. Vol. 54(Supplement 1). 2017:11. MirzaR , GuyattG . In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks. Annals of Internal Medicine, ACP Journal Club 2019 Feb 19;170(4):JC21. [DOI: 10.7326/ACPJ201902190-021] [PMID: 30776810]RoustitM , CracowskiJL , GiaiJ , SubtilF , GagetO , MouhibM , et al. In: On-demand sildenafil as a treatment for raynaud's phenomenon: A series of N-of-1 trials. 5th Systemic Sclerosis World Congress. Bordeaux France. Vol. 3(Supplement 1). 2018:175-176. RoustitM , GagetO , MouhibM , Lotito A, KhouriC , Blaise S et al. On demand sildenafil as a treatment of raynaud's phenomenon: A series of n-of-1 trials. In: 13th Congress of the European Association for Clinical Pharmacology and Therapeutics and EACPT 2017. Prague Czechia. Vol. 39(8 Supplement 1). 2017:e4. RoustitM , GiaiJ , GagetO , KhouriC , MouhibM , LotitoA , et al. On-demand Sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. Annals of Internal Medicine2018;169(10):694-703. [CLINICALTRIALS.GOV: NCT02050360] [DOI: 10.7326/M18-0517]RoustitM , GiaiJ , GagetO , KhouriC , MouhibM , LotitoA , et al. On-demand Sildenafil as a treatment of Raynaud's phenomenon: a series of N-of-1 trials (abstract # CO-51). In: Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical Research Centers, CIC Meeting. Vol. 31(Suppl 1). Rouen, France, April 19-21, 2017:16. ">Roustit 2018</a> ‐ a series of N of 1 trials) and three studies lacked a placebo arm (<a href="./references#CD014089-bbs2-0010" title="Bellando-RandoneS , MiniatiI , GuiducciS , LetiziaCM , BlagojevicJ , FioriG , et al. Sildenafil increases vasodilation in systemic sclerosis: an interim analysis from a single centre pilot study [abstract #593]. In: Arthritis and Rheumatology. Vol. 62 Suppl 10. 2010:S248. [DOI: DOI: 10.1002/art.30166]">Bellando‐Randone 2010</a>; <a href="./references#CD014089-bbs2-0012" title="ParkJK , LeeEY , YoonMJ , KimYK , ParkCS , GilesJT , et al. Head to head comparison of Udenafil versus Amlodipine in the treatment of secondary Raynaud's phenomenon in the treatment of secondary Raynaud's Phenomenon: a double-blind, randomized cross-over study. In: Scientific Abstracts. 2013. ">Park 2013</a>; <a href="./references#CD014089-bbs2-0014" title="WatanabeH , NishioS , OhmaeE , et al. Sildenafil improves fore arm blood flow in patients with Raynaud’s phenomenon (abstract P1207). In: European Heart Journal. Vol. 25. 2004:202. ">Watanabe 2004</a>). Of the 3 studies awaiting classification, one, <a href="./references#CD014089-bbs2-0017" title="ZamiriB , KomanAL , SmithBP , SmithTL , HoldenM , RushingJ , et al. Double-blind, placebo-controlled trial of Sildenafil for the management of primary Raynaud's phenomenon (Abstract SAT0342). Annals of Rheumatic Diseases2004;63 Suppl 1:484–5. ">Zamiri 2004</a>, is a conference abstract, and we have tried to contact the authors for additional information. The other two are trials listed on clinical trial registries and reported to be complete, but there is no data available (<a href="./references#CD014089-bbs2-0015" title="EUCTR2007-000397-23-DE (2007). A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in patients with secondary Raynaud's disease. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000397-23 (first received May 29, 2007). NCT00528242. Safety, tolerability, and pharmacodynamic profile of oral 2101 in secondary Raynaud's disease. clinicaltrials.gov/ct2/show/NCT00528242 (first received 12 September 2007). ">NCT00528242</a>; <a href="./references#CD014089-bbs2-0016" title="NCT00707187. Trial of IC351 in female scleroderma patients with Raynaud's and sexual dysfunction. clinicaltrials.gov/ct2/show/NCT00707187 (first received 30 June 2008). ">NCT00707187</a>). </p> </section> </section> <section id="CD014089-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed each included study for risk of bias. We present our assessments in the <a href="./references#CD014089-sec-0117" title="">Characteristics of included studies</a> and <a href="#CD014089-fig-0002">Figure 2</a> and summarise these in <a href="#CD014089-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD014089-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014089-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014089-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014089-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014089-sec-0060"> <h4 class="title">Allocation</h4> <p>We judged three studies to be at low risk of selection bias (<a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). They used a random digits table or computer‐generated randomisation software. Furthermore, the method of allocation concealment was described. Authors of the six remaining six studies described them as randomised but no further information was provided (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>). We judged these studies to be at unclear risk of selection bias. </p> </section> <section id="CD014089-sec-0061"> <h4 class="title">Blinding</h4> <p>We judged one study to be at high risk as participants were able to independently successfully identify which group they were randomised to (<a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>). Authors of the remaining studies described them as double‐blind, and we judged them to be at low risk of bias (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). </p> </section> <section id="CD014089-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four studies were judged to be at high risk of attrition bias due to the number of dropouts and the dropout rates differing significantly between the active treatment and placebo arms, and the use of per‐protocol analyses (<a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>). We judged the remaining five studies to be at low risk of attrition bias (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>) </p> </section> <section id="CD014089-sec-0063"> <h4 class="title">Selective reporting</h4> <p>We judged four studies to be at unclear risk of reporting bias as there were no protocols to compare planned outcomes to reported outcomes (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>). We judged the remaining five studies to be at low risk of bias (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). </p> </section> <section id="CD014089-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential sources of bias we considered were carryover effects for cross‐over studies and similarity in baseline characteristics for parallel studies. We judged one study to be at high risk of bias due to suspected carryover effects that lasted throughout the washout phase and beyond (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>). We judged the remaining studies to be at low risk of other bias (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). </p> </section> </section> <section id="CD014089-sec-0065"> <h3 class="title" id="CD014089-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD014089-tbl-0001"><b>Summary of findings 1</b> Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</a> </p> <p>All nine included studies compared PDE5i to a placebo.</p> <section id="CD014089-sec-0066"> <h4 class="title">Major outcomes</h4> <p><a href="./full#CD014089-tbl-0001">summary of findings Table 1</a> provides an overall summary of the major outcomes below. </p> <section id="CD014089-sec-0067"> <h5 class="title">Frequency of attacks</h5> <p>Based on data from eight studies, we found that PDE5i may reduce the frequency of attacks of Raynaud's phenomenon by a small amount per week compared to placebo (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The mean frequency of attacks per week was 24 in participants given a placebo. Participants treated with PDE5i experienced three fewer attacks, resulting in 21 attacks per week (mean difference (MD) ‐3.07, 95% CI ‐5.15 to ‐1.00; I<sup>2</sup>= 74%; 397 participants; low‐certainty evidence; <a href="./references#CD014089-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD014089-sec-0068"> <h5 class="title">Duration of attacks</h5> <p>Based on data from eight studies, we found that PDE5i may result in a small reduction in the duration of Raynaud's phenomenon attacks per day compared to placebo (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The mean duration of attacks per day with placebo was 55 minutes and was reduced by 5.3 minutes per day with PDE5i (MD ‐5.31 minutes, 95% CI ‐8.90 to ‐1.71; I<sup>2</sup>= 70%; 397 participants; low‐certainty evidence; <a href="./references#CD014089-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD014089-sec-0069"> <h5 class="title">Severity of attacks</h5> <p><a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a> measured severity of Raynaud's attacks using a 10 cm visual analogue scale, where 0 equals no symptoms and 10 corresponds to maximal severity. Mean severity of Raynaud's attack was 3.7 with placebo; this was reduced by 2 points with PDE5i (MD ‐2.05, 95% CI ‐2.68 to ‐1.42; 8 participants; very low‐certainty evidence; <a href="./references#CD014089-fig-0006" title="">Analysis 1.3</a>). This corresponds to an absolute difference of 20% improvement (27% better to 14% better). </p> </section> <section id="CD014089-sec-0070"> <h5 class="title">Pain</h5> <p>Four studies measured pain intensity using a 10 cm visual analogue scale, where 0 equals no symptoms and 10 corresponds to maximal severity (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>). Mean pain in the placebo group was 3; this was reduced by 0.1 points with PDE5i (MD ‐0.10, 95% CI ‐0.78 to 0.57; I<sup>2</sup>= 69%; 273 participants; low‐certainty evidence; <a href="./references#CD014089-fig-0007" title="">Analysis 1.4</a>). This corresponds to an absolute difference of 1% improvement (7% better to 6% worse). </p> </section> <section id="CD014089-sec-0071"> <h5 class="title">Patient global assessment</h5> <p><a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a> measured patient global assessment using a 0 to 10 scale, with lower scores indicating less disability. The mean score in the placebo group was 9.2, and it was 3.6 points better with PDE5i (MD ‐3.59, 95% CI ‐4.45 to ‐2.73; 24 participants; low‐certainty evidence; <a href="./references#CD014089-fig-0008" title="">Analysis 1.5</a>). This corresponds to an absolute difference of 36% improvement (45% better to 27% better). </p> </section> <section id="CD014089-sec-0072"> <h5 class="title">Withdrawals due to adverse events</h5> <p>Four studies reported no withdrawals due to adverse events (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>). In five studies, the rate of withdrawals during treatment with PDE5i ranged from 2% to 20% compared with 2% to 4% in the placebo group (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). Based on moderate‐certainty evidence, PDE5i probably increases slightly the likelihood of withdrawing from treatment due to an adverse event. See <a href="#CD014089-tbl-0002">Table 1</a> for further details. </p> <div class="table" id="CD014089-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data on withdrawals due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PDE5i</b> </p> <p>Number of events/number of participants (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>Number of events/number of participants (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agarwal 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/26 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herrick 2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andrigueti 2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/21 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caglayan 2012*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/53 (2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/53 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fries 2005*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20 (10)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laumann 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenoy 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25 (4)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schiopu 2009*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018*: primary Raynaud's</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/57 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018*: secondary Raynaud's</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/65 (18)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/65 (2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Cross‐over studies: data show the number of events that occurred while on the treatment or control arm regardless of period </p> </div> </div> </section> <section id="CD014089-sec-0073"> <h5 class="title">Serious adverse events</h5> <p>Seven studies reported no serious adverse events (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The rate of serious adverse events was 2% during treatment with PDE5i (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>). In participants given a placebo, the rate ranged from 0.8% to 4% (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>). PDE5i probably results in little or no difference in serious adverse events. See <a href="#CD014089-tbl-0003">Table 2</a> for further details. </p> <div class="table" id="CD014089-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on serious adverse advents</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PDE5i</b> </p> <p>Number of events/number of participants (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>Number of events/number of participants (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agarwal 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/26 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herrick 2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andrigueti 2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caglayan 2012*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/53 (2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/53 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fries 2005*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laumann 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenoy 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schiopu 2009*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/42 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/42 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018: primary Raynaud's*<sup>#</sup> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/54 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/102(0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018: secondary Raynaud's*<sup>#</sup> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/64 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/122 (0.8)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Cross‐over studies: data show the number of events that occurred while on the treatment or control arm regardless of period<br/><sup>#</sup>Data reported for combined placebo groups (both 4 mg and 20 mg treatment arms) </p> </div> </div> </section> </section> <section id="CD014089-sec-0074"> <h4 class="title">Minor outcomes</h4> <section id="CD014089-sec-0075"> <h5 class="title">Function</h5> <p>Two studies measured functional ability using the SF‐36 physical function subscale (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). This scale ranges from 0 to 100, where higher scores equals better function. The MD was 2.59 (95% CI 0.17 to 5.01; <a href="./references#CD014089-fig-0009" title="">Analysis 1.6</a>), indicating a small improvement that is not clinically relevant. </p> </section> <section id="CD014089-sec-0076"> <h5 class="title">Raynaud's Condition Score (RCS)</h5> <p>The RCS is a validated measure assessing the difficulty a patient had that day with Raynaud's phenomenon. RCS is assessed with a 10 cm visual analogue scale (VAS) where 0 represents no difficulty and 10 represents extreme difficulty. Seven studies measured the RCS (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The pooled MD for RCS was ‐0.78 (95% CI ‐1.23 to ‐0.32; 237 participants; <a href="./references#CD014089-fig-0010" title="">Analysis 1.7</a>), indicating that PDE5i were slightly better than placebo in reducing the amount of difficulty experienced due to Raynaud's phenomenon. </p> </section> <section id="CD014089-sec-0077"> <h5 class="title">Physician global assessment</h5> <p><a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a> measured physician‐assessed overall Raynaud's phenomenon disease activity with a 10 cm VAS (higher score indicates worse Raynaud's phenomenon condition). The MD was ‐2.85 (95% CI ‐3.71 to ‐1.99; 24 participants). This indicates that PDE5i resulted in a clinically important improvement in physician global assessment compared to placebo (<a href="./references#CD014089-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD014089-sec-0078"> <h5 class="title">Digital ulcers healed</h5> <p>This outcome was defined as the number of people with existing or new ulcers, or the number of ulcers that healed by the end of the study (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>; <a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). In each study, PDE5i were associated with higher rates of ulcer healing (78% to 100%) compared to placebo (0% to 38%). The pooled risk ratio (RR) from two parallel studies was 2.12 (95% CI 1.05 to 4.26; <a href="./references#CD014089-fig-0012" title="">Analysis 1.9</a>), indicating that participants with digital ulcers who were given PDE5i were more than twice as likely to have their ulcers healed compared to those in the placebo group. </p> <p>In <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a> (a cross‐over study), during treatment with PDE5i, the chronic digital ulcers in six people with secondary Raynaud’s phenomenon began to heal during treatment, but the ulcers reappeared or progressed after PDE5i treatment was stopped. During treatment with placebo, existing ulcers did not heal. </p> <p>In <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a> (a cross‐over study), 100% of digital ulcers healed during PDE5i treatment as compared with 23% of ulcers in those given a placebo. </p> </section> <section id="CD014089-sec-0079"> <h5 class="title">New digital ulcers</h5> <p><a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a> measured the number of people with new digital ulcers that developed during the study and <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a> measured the number of new digital ulcers. </p> <p>In <a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>, only one out of 27 participants treated with PDE5i developed a new ulcer compared to nine out of 26 participants given a placebo (RR 0.11, 95% CI 0.01 to 0.79; <a href="./references#CD014089-fig-0013" title="">Analysis 1.10</a>). </p> <p>In <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>, a cross‐over study with 24 people, one new digital ulcer was reported in participants given tadalafil therapy compared to 13 given a placebo. </p> </section> <section id="CD014089-sec-0080"> <h5 class="title">Adverse effects</h5> <p>Adverse effects were reported in various ways across the studies. We were unable to extract the total number of adverse events from the included studies, so we extracted data on the most frequently reported specific adverse events. </p> <p>We extracted data on headaches, myalgia, and dizziness from the parallel RCTs. The RR for headaches was 1.76 (95% CI 1.04 to 2.97; I<sup>2</sup>= 1%; 3 studies; <a href="./references#CD014089-fig-0014" title="">Analysis 1.11</a>), indicating an increase in headaches in the PDE5i group compared to placebo. In the cross‐over studies, the percent of headaches reported during the PDE5i period ranged from 15% to 52% compared to 0% to 41.7% during the placebo period. The number of participants experiencing headaches in individual studies were as follows: in <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>, 52% PDE5i versus 26% placebo; in <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>, 15% PDE5i versus 0% placebo; in <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>, 15% PDE5i versus 18% placebo; and in <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>, 37.5% PDE5i versus 41.7% placebo. </p> <p>The RR for myalgia (muscle pain) was 1.31 (95% CI 0.52 to 3.29; I<sup>2</sup>= 12%; 2 studies), which was compatible with both a reduction in myalgia and an important increase. Only one cross‐over study reported myalgia (<a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). It was reported in 12.5% and 8.3% of PDE5i and placebo participants, respectively. </p> <p>Based on one parallel RCT (<a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a>), the RR for dizziness was 1.20 (95% CI 0.36 to 3.99) with the wide CI indicating uncertainty around the estimate. In the cross‐over studies, dizziness was reported in 5% to 33% of participants treated with PDE5i, compared to 16% of those given a placebo (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). In <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>, there was an increase in dizziness during the PDE5i period (33%) compared to the placebo (7%). In <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>, only one participant reported dizziness during the PDE5i period and none during the placebo period. In <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>, the rates of dizziness were similar in PDE5i (20.8%) and placebo (16.7%). </p> <section id="CD014089-sec-0081"> <h6 class="title">Results from search of regulatory websites</h6> <p>Two medicine regulatory agencies – the US Food and Drug Administration’s MedWatch programme and the European Medicines Evaluation Agency – published the following serious warnings for PDE5i as a class on their websites: </p> <p> <ul id="CD014089-list-0020"> <li> <p>sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic ischaemic optic neuropathy (NAION); and </p> </li> <li> <p>sudden decrease or loss of hearing.</p> </li> </ul> </p> </section> </section> <section id="CD014089-sec-0082"> <h5 class="title">Treatment preference and general improvement</h5> <p>None of the included studies reported these minor outcomes.</p> </section> </section> <section id="CD014089-sec-0083"> <h4 class="title">Subgroup analyses</h4> <section id="CD014089-sec-0084"> <h5 class="title">By Raynaud's phenomenon type (primary or secondary)</h5> <p>Most of the studies included participants with secondary Raynaud's phenomenon. Two studies included both primary and secondary Raynaud's, but the primary participants made up only 12% of the total study population (<a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>). <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a> reported subgroup differences with an increased efficacy of vardenafil in participants with primary Raynaud's phenomenon and secondary Raynaud's phenomenon with limited cutaneous systemic scleroderma compared with other subsets of participants with secondary Raynaud's phenomenon, but the subgroup sample sizes were small. One study had separate study arms for primary and secondary Raynaud's (<a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a>). The test for subgroup differences between primary and secondary Raynaud's phenomenon was not statistically significant for the outcomes of frequency and duration of attacks (<a href="./references#CD014089-fig-0015" title="">Analysis 2.1</a>; <a href="./references#CD014089-fig-0016" title="">Analysis 2.2</a>). </p> </section> <section id="CD014089-sec-0085"> <h5 class="title">By type of phosphodiesterase‐5 inhibitor</h5> <p>The test for subgroup differences comparing the four different PDE5i (tadalafil, sildenafil, vardenafil, and PF‐00489791) was not statistically significant for the outcomes of frequency and duration of attacks (<a href="./references#CD014089-fig-0017" title="">Analysis 3.1</a>; <a href="./references#CD014089-fig-0018" title="">Analysis 3.2</a>) </p> </section> <section id="CD014089-sec-0086"> <h5 class="title">By sildenafil dosing regime</h5> <p>We only explored the sildenafil dosing regime as the other drugs used the same dosing regime. The test for subgroup differences comparing sildenafil 100 mg per day to 200 mg per day was not statistically significant for the outcome of frequency of attack but was statistically significant for duration of attack in minutes. At 200 mg per day, there evidence of little to no difference between the sildenafil and placebo groups (MD ‐0.60, 95% CI ‐1.60 to 0.40), while at 100 mg per day, there was evidence of an important difference in favour of sildenafil (MD ‐13.11, 95% CI ‐20.73 to ‐5.50). Test for subgroup differences: Chi² = 10.20, degree of freedom = 1 (P = 0.001), I² = 90.2% (<a href="./references#CD014089-fig-0019" title="">Analysis 4.1</a>; <a href="./references#CD014089-fig-0020" title="">Analysis 4.2</a>). </p> </section> <section id="CD014089-sec-0087"> <h5 class="title">By RCT type (cross‐over compared to parallel)</h5> <p>We conducted a post hoc subgroup analysis to see if the study design (parallel versus cross‐over reporting endline data versus cross‐over reporting change of changes data) had an impact on the results. The test for subgroup differences indicated there was no statistically significant difference between subgroups for the outcomes of frequency and duration of attack (<a href="./references#CD014089-fig-0021" title="">Analysis 5.1</a>; <a href="./references#CD014089-fig-0022" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD014089-sec-0088"> <h4 class="title">Sensitivity analyses</h4> <section id="CD014089-sec-0089"> <h5 class="title">Study quality</h5> <p>The main analysis was based on studies at low or unclear risk of bias for selection and detection bias. One study was at high risk of detection bias due to lack of blinding (<a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>). Adding this study to the analysis did not substantively change the results for frequency and duration of attacks. Restricting the analysis to the three studies that clearly described their methods for sequence generation, allocation concealment, and blinding (<a href="./references#CD014089-bbs2-0002" title="AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of Sildenafil on the microvascular blood flow and on the endothelial progenitor cells in patients with early systemic sclerosis: a randomized, double-blind, placebo-controlled study. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; San Diego (CA). 2013 Oct 25-30. [Abstract 1813]AndriguetiFV , EbbingPC , ArismendiMI , KayserC . Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clinical and Experimental Rheumatology2017;35 Suppl 106:S151-8. ">Andrigueti 2017</a>; <a href="./references#CD014089-bbs2-0003" title="CaglayanE , AxmannS , HellmichM , MoinzabehP , RosenkranzS . Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Archives of International Medicine2012;172(15):1182-4. [CLINICALTRIALS.GOV: NCT01291199] [EUROPEAN UNION CLINICAL TRIALS REGISTER: EUCTR2005-000295-41-DE]CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , Hellmich M et al. Vardenafil in patients with raynaud's syndrome. In: European Society of Cardiology and ESC Congress. Paris, France. Vol. 32(SUPPL. 1). 2011:655. CaglayanE , AxmannS , HuntgeburthM , ErdmannE , RosenkranzS , HellmichM , et al. Vardenafil improves clinical symptoms and digital blood flow in patients with primary and secondary raynaud syndrome - Results from a randomized controlled trial. In: American Heart Association's Scientific Sessions: Orlando and FL United States. Vol. 124(21 SUPPL. 1). 2011:https://www.ahajournals.org/browse/toc/circ/124/suppl_21/meeting-abstract-long-toc/b5331. ">Caglayan 2012</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>), resulted in a similar estimate to the main analysis for frequency of attacks per day (MD ‐4.65, 95% CI ‐8.42 to ‐0.89) and a slightly larger estimate for duration of attacks in minutes (MD ‐13.02, 95% CI ‐19.21 to ‐6.83). </p> </section> <section id="CD014089-sec-0090"> <h5 class="title">Study duration</h5> <p>All the studies were in the range of four to eight weeks, so we did not conduct a sensitivity analysis given the similarity of their durations. </p> </section> <section id="CD014089-sec-0091"> <h5 class="title">Diagnostic inclusion criteria used in the study</h5> <p>The majority of the studies used ARA/ACR criteria (<a href="./references#CD014089-bbs2-0037" title="MasiAT , RodnanGP , Medsger TA Jr. ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis and Rheumatism1980;23(5):581-90.">Masi 1980</a>) for systemic sclerosis and one used LeRoy criteria (<a href="./references#CD014089-bbs2-0035" title="LeRoyEC , MedsgerTA . Raynaud's phenomenon: a prosposal for classification. Clinical and Experimental Rheumatology1992;10:485-8.">LeRoy 1992</a>). We did not undertake a sensitivity analysis given the similarity of the inclusion criteria used. </p> </section> <section id="CD014089-sec-0092"> <h5 class="title">Time of the year study was performed</h5> <p>Two studies were conducted during warmer months (<a href="./references#CD014089-bbs2-0004" title="FriesR , ShariatK , vonWilmowskyH , BohmM . Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation2005;112(19):2980-5. ">Fries 2005</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). The other studies were conducted throughout the year or this information was not reported. We did not conduct a sensitivity analysis given the paucity of information. Two studies investigated whether there was a relationship with the environment temperature and found outdoor temperature had no effect on the number of attacks of Raynaud's phenomenon (<a href="./references#CD014089-bbs2-0005" title="HerrickAL , Van Den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces raynauds attack frequency in systemic sclerosis. In: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09. Atlanta and GA United States. Vol. 60(SUPPL. 10). 2009:472. HerrickAL , Van den HoogenF , GabrielliA , TamimiN , ReidC , O'ConnellD , et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism2011;63(3):775-82. ">Herrick 2011</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>). </p> </section> <section id="CD014089-sec-0093"> <h5 class="title">Estimations or imputations for measures of variance</h5> <p>For our main analysis, we assumed a correlation coefficient of 0.8 in our calculations to determine variance in three cross‐over studies (<a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a>; <a href="./references#CD014089-bbs2-0008" title="SchiopuE , HsuVM , ImpensAJ , RothmanJA , McCloskeyDA , WilsonJE , et al. Randomized placebo-controlled trial of Tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology2009;36(10):2264-8. ">Schiopu 2009</a>; <a href="./references#CD014089-bbs2-0009" title="ShenoyP , AgarwalV , MisraR , KumarS , ChoudharyS , JhaL , et al. Tadalafil is effective in the management of resistant secondary Raynaud's phenomenon and improves endothelial function. In: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meetings 2009 and Rheumatology '09. Glasgow, United Kingdom. Vol. 48(SUPPL. 1). 2009:i.26 OP77. ShenoyPD , KumarS , JhaLK , ChoudharySK , SinghU , MisraR , et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010;49(12):2420-8. [CLINICALTRIALS.GOV: NCT00626665]">Shenoy 2010</a>). We tested the robustness of this estimate by using a correlation coefficient of 0.5 and found that the estimates for frequency of attacks (MD ‐5.31, 95% CI ‐8.90 to ‐1.71 to MD ‐4.87, 95% CI ‐8.53 to ‐1.17) and duration of attack (MD ‐3.07, 95% CI ‐5.15 to ‐1.00 to MD ‐2.60, 95% CI ‐4.44 to ‐0.76) did not change substantively (<a href="./references#CD014089-fig-0023" title="">Analysis 6.1</a>; <a href="./references#CD014089-fig-0024" title="">Analysis 6.2</a>). </p> <section id="CD014089-sec-0094"> <h6 class="title">Sources of data</h6> <p>Data from <a href="./references#CD014089-bbs2-0001" title="AgarwalV , GhoshP , SharmaA , BhakuniDS , KumarS , SinghUM , et al. Efficacy of Tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicentric study. Arthritis and Rheumatism2010;62 Suppl 10:2086. [CLINICALTRIALS.GOV: NCT01117298]">Agarwal 2010</a> were published in an abstract and the author provided a PowerPoint presentation with additional details. We estimated measures of variance from graphs using PlotDigitizer. We obtained data for <a href="./references#CD014089-bbs2-0006" title="LaumannA . Tadalafil for the treatment of secondary Raynaud's phenomenon (unpublished data). www.clinicaltrials.gov/ct2/show/NCT00822354. ">Laumann 2010</a> and <a href="./references#CD014089-bbs2-0007" title="Pfizer. A phase 2a randomized double-blinded, placebo and active controlled two cohort two doses cross-over multi-center clinical study to assess efficacy of a once daily administration of a phosphodiesterase 5 inhibitor (pf-00489791) for the treatment of vasospasm in primary and secondary Raynaud's phenomenon. www.clinicaltrials.gov/ct2/show/NCT010904922018. [EUROPEAN UNION CLINICAL TRIAL REGISTRY: EUCTR2010-019009-40-HU]">Pfizer 2018</a> from <a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014089-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014089-sec-0095"></div> <section id="CD014089-sec-0096"> <h3 class="title" id="CD014089-sec-0096">Summary of main results</h3> <p>We included nine studies with a total of 411 participants in this review. Six of the studies were cross‐over while three were parallel RCTs. The majority of the studies were conducted in people with secondary Raynaud's phenomenon. Overall, evidence from the included studies ranged from very low to low certainty, and indicated that PDE5i may be slightly more beneficial than placebo in reducing the frequency, duration, and severity of Raynaud's attacks in people with systemic sclerosis. However, there may be little to no difference in associated pain. PDE5i were also associated with more withdrawals from treatment as a result of intolerable treatment effects but probably result in little to no difference in the number of serious adverse events compared to placebo (see <a href="./full#CD014089-tbl-0001">summary of findings Table 1</a>). </p> <p>The subgroup analyses by individual PDE5i (sildenafil, tadalafil, and vardenafil), and between primary and secondary Raynaud's phenomenon for the outcomes of frequency and duration of attack, showed no evidence of statistically significant subgroup differences. </p> </section> <section id="CD014089-sec-0097"> <h3 class="title" id="CD014089-sec-0097">Overall completeness and applicability of evidence</h3> <p>This review has a few limitations that should be noted.</p> <p>The first limitation was the quality of the included studies. The risk of selection bias in the majority of studies was unclear as a result of inadequate reporting of the methodology used. Future studies need to report the methodology more completely to allow review authors to assess the quality of the study data. </p> <p>A second limitation of this review was the small number of studies as well as the small sample sizes of those studies. As a result, the overall small sample size was a problem, especially for subgroup analyses and for outcomes that were not reported by many studies. For outcomes with small sample sizes, the results often have large confidence intervals and are imprecise. </p> <p>A third limitation was the short duration of the included studies. Studies of longer duration may show more benefit with the use of PDE5i as there is usually a high placebo effect with Raynaud's phenomenon treatment initially. </p> <p>The lack of publication of negative studies remains a concern. We plan to assess this with funnel plots in future updates of this review where at least 10 studies report data on an outcome. As well, two studies (total 137 participants) were registered with clinicaltrials.gov and completed in 2002 and 2008. However, the results from these studies have not been published, and we are uncertain what the impact of these results may be on our overall estimates of effect. </p> <p>Lastly, all the included studies had a majority of participants with Raynaud's phenomenon secondary to systemic sclerosis. Hence, the results of this review may be more applicable to these people. However, the test for subgroup differences between primary and secondary Raynaud's did not indicate a difference in the results between the two groups. Since secondary Raynaud's phenomenon (especially scleroderma) is more difficult to treat, PDE5i may be just as effective in the less severe primary Raynaud's phenomenon and Raynaud's phenomenon secondary to other connective diseases. </p> </section> <section id="CD014089-sec-0098"> <h3 class="title" id="CD014089-sec-0098">Quality of the evidence</h3> <p>We assessed the certainty of the evidence of studies included in this review using the GRADE approach (<a href="./references#CD014089-bbs2-0023" title="Grading Working Group. Grading quality of evidence and strength of recommendations. BMJ2008;336(7653):1106-10.">GRADE 2008</a>). The evidence from this review ranged from very low to moderate. Many of the studies failed to fully describe the methods used to conduct the study. The most commonly encountered issues when assessing the quality of the studies were the lack of full descriptions of the random sequence generation, allocation concealment, and performance and outcome assessment blinding. Most publications noted that the study was randomised and double‐blind, without providing further details to assess these assertions. However, the main concerns that affected the certainty of the evidence were heterogeneity and small sample sizes. Three studies were not published in peer‐reviewed journals; we obtained their data from <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> or from the study authors. </p> </section> <section id="CD014089-sec-0099"> <h3 class="title" id="CD014089-sec-0099">Potential biases in the review process</h3> <p>An extensive and sensitive electronic search of all important databases, including clinical trial registers, was performed to ensure retrieval of as many studies as possible. In addition, at least two review authors performed the majority of the steps of the review, with consultation of a third review author for any disagreements. The studies reported their results in a variety of ways, and we had to transform or impute data in order to use them in a meta‐analysis. While we checked our assumptions with sensitivity analyses, this may have had an impact on the precision of the estimates. </p> </section> <section id="CD014089-sec-0100"> <h3 class="title" id="CD014089-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>The results of our review are in agreement with the <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a> review, which included six studies. <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a> analysed the average daily frequency and duration of attacks as well as the Raynaud's Condition Score. We found that PDE5i reduced the frequency of daily Raynaud's phenomenon attacks by an average of 0.49 (95% CI ‐0.71 to ‐0.17). </p> <p>We looked at the reduction in the average number of attacks over a one‐week period, and found a reduction of three attacks. This would equal a daily reduction of 0.43 attacks, which is similar to that found in <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a>. Similar to our review, <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a> found a reduction in the average daily duration of Raynaud's phenomenon. Lastly, both reviews found a small, though likely not clinically important, reduction in the Raynaud's Condition Score: in <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a>, the mean reduction was ‐0.46 (95% CI ‐0.74 to ‐0.17) while we found a reduction of ‐0.78 (95% CI ‐1.23 to ‐0.32). Hence, the results of the <a href="./references#CD014089-bbs2-0043" title="RoustitM , BlaiseS , AllanoreY , CarpentierPH , CaglayanE , CracowskiJL . Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of Rheumatic Disease2013;72(10):1696-9. [DOI: 10.1136/annrheumdis-2012-202836]">Roustit 2013</a> review are in agreement with our review, although our review includes additional studies and analysed more outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014089-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram; CT=clinicaltrials.gov; ICTRP=International Clinical Trials Registry Platform" data-id="CD014089-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram; CT=clinicaltrials.gov; ICTRP=International Clinical Trials Registry Platform </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014089-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014089-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 1: Frequency of attacks (average per week)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 2: Duration of attacks (average attack duration, minutes)" data-id="CD014089-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 2: Duration of attacks (average attack duration, minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 3: Severity of attacks (0 to 10 VAS)" data-id="CD014089-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 3: Severity of attacks (0 to 10 VAS)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 4: Pain (0 to 10 VAS)" data-id="CD014089-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 4: Pain (0 to 10 VAS)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 5: Patient global assessment" data-id="CD014089-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 5: Patient global assessment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 6: Function" data-id="CD014089-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 6: Function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 7: Raynaud's Condition Score" data-id="CD014089-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 7: Raynaud's Condition Score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 8: Physician global assessment" data-id="CD014089-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 8: Physician global assessment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 9: Number of people with healed digital ulcers" data-id="CD014089-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 9: Number of people with healed digital ulcers</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 10: Number of people with new digital ulcers" data-id="CD014089-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 10: Number of people with new digital ulcers</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PDE5i vs placebo, Outcome 11: Adverse effects" data-id="CD014089-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: PDE5i vs placebo, Outcome 11: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup: primary and secondary Raynaud's phenomenon, Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup: primary and secondary Raynaud's phenomenon, Outcome 1: Frequency of attacks (average per week) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup: primary and secondary Raynaud's phenomenon, Outcome 2: Duration of attacks (average attack duration, minutes)" data-id="CD014089-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup: primary and secondary Raynaud's phenomenon, Outcome 2: Duration of attacks (average attack duration, minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup: PDE5i inhibitor type, Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup: PDE5i inhibitor type, Outcome 1: Frequency of attacks (average per week) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup: PDE5i inhibitor type, Outcome 2: Duration of attacks (minutes)" data-id="CD014089-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Subgroup: PDE5i inhibitor type, Outcome 2: Duration of attacks (minutes)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup: sildenafil dosing regimen, Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Subgroup: sildenafil dosing regimen, Outcome 1: Frequency of attacks (average per week) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup: sildenafil dosing regimen, Outcome 2: Duration of attacks (average attack duration, minutes)" data-id="CD014089-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Subgroup: sildenafil dosing regimen, Outcome 2: Duration of attacks (average attack duration, minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup: trial design, Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Subgroup: trial design, Outcome 1: Frequency of attacks (average per week) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup: trial design, Outcome 2: Duration of attacks (average attack duration, minutes)" data-id="CD014089-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Subgroup: trial design, Outcome 2: Duration of attacks (average attack duration, minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 1: Frequency of attacks (average per week)" data-id="CD014089-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 1: Frequency of attacks (average per week) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 2: Duration of attacks (average attack duration, minutes)" data-id="CD014089-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 2: Duration of attacks (average attack duration, minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 3: Severity of attacks (0 to 10 VAS)" data-id="CD014089-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 3: Severity of attacks (0 to 10 VAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 4: Pain (0 to 10 VAS)" data-id="CD014089-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 4: Pain (0 to 10 VAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014089-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/urn:x-wiley:14651858:media:CD014089:CD014089-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 5: Patient global assessment" data-id="CD014089-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_t/tCD014089-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis: PDE5i vs placebo (major outcomes), Outcome 5: Patient global assessment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014089/media/CDSR/CD014089/image_n/nCD014089-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014089-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with Raynaud's phenomenon (primary or secondary)<br/><b>Setting:</b> outpatient clinics<br/><b>Intervention:</b> phosphodiesterase 5 inhibitors (PDE5i) (tadalafil, sildenafil, vardenafil)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell table-tint" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Without PDE5i</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>With PDE5i</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Difference</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of attacks per week<br/>Follow‐up: range 4 weeks to 8 weeks<br/>Number of participants: 397 </p> <p>(8 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of attacks per week without PDE5i was 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of attacks per week with PDE5i was 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.07 lower<br/>(5.15 lower to 1.00 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may reduce the frequency of attacks of Raynaud's phenomenon by a small amount per week </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of attacks per day (minutes)<br/>Follow‐up: range 4 weeks to 8 weeks<br/>Number of participants: 397(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean duration of attacks per day without PDE5i was 55 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean duration of attacks per day with PDE5i was 50 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5.31 minutes lower<br/>(8.90 lower to 1.71 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may result in a small reduction in the duration of Raynaud's phenomenon attacks per day </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of Raynaud's attack<br/>assessed with: 0 to 10 VAS; higher score means worse severity<br/>Follow‐up: mean 4 weeks </p> <p>Number of participants: 8</p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean severity of Raynaud's attack without PDE5i was 3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean severity of Raynaud's attack with PDE5i was 1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.1 lower<br/>(2.7 lower to 1.4 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether PDE5i reduces the severity of an attack due to very low‐certainty evidence. </p> <p>Absolute difference: 20% better (14% better to 27% better)</p> <p>Relative per cent change: 57% better (38% better to 73% better)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity<br/>assessed with: 0 to 10 VAS; higher score means worse pain<br/>Follow‐up: range 4 weeks to 8 weeks </p> <p>Number of participants: 273</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain without PDE5i was 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean pain with PDE5i was 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.10<br/>(0.78 lower to 0.57 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may result in little to no difference in pain</p> <p>Absolute difference: 1% better (7.8% better to 5.7% worse)</p> <p>Relative per cent change: 3% better (26% better to 19% worse)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient global<br/>assessed with: 0 to 10 VAS; higher score means worse global assessment<br/>Follow‐up: mean 6 weeks </p> <p>Number of participants: 24</p> <p>(1 RCT)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean patient global without PDE5i was 9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean patient global with PDE5i was 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.6 lower<br/>(4.45 lower to 2.73 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDE5i may improve the patient's global assessment of their disease</p> <p>Absolute difference: 36% better (27% better to 45% better)</p> <p>Relative per cent change: 39% better (30% better to 48% better)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events</p> <p>Follow‐up: range 4 weeks to 8 weeks</p> <p>Number of participants: 411</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>See 'What happens' column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four studies reported no withdrawals due to adverse events. In five studies, the rate of withdrawals during treatment with PDE5i ranged from 2% to 20% compared with 2% to 4% in the placebo group. </p> <p>PDE5i probably increases slightly the likelihood of withdrawing from treatment due to an adverse event. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> <p>Follow‐up: range 4 weeks to 8 weeks</p> <p>Number of participants: 411</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>See 'What happens' column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seven studies reported no serious adverse events. The rate of serious adverse events ranged from 2% during treatment with PDE5i to 4% with placebo. </p> <p>PDE5i probably results in little or no difference in serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision (few participants)<br/><sup>b</sup>Downgraded one level due to concerns about inconsistency (unexplained heterogeneity: I<sup>2</sup>≥ 69%)<br/><sup>c</sup> Downgraded two levels due to very serious concerns about imprecision<br/><sup>d</sup> Downgraded one level due to concerns about both risk of bias and publication bias (unpublished data from clinicaltrials.gov) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phosphodiesterase 5 inhibitors (PDE5i) compared to placebo in the treatment of Raynaud's phenomenon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014089-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data on withdrawals due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PDE5i</b> </p> <p>Number of events/number of participants (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p>Number of events/number of participants (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agarwal 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/27 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/26 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herrick 2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andrigueti 2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/21 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caglayan 2012*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/53 (2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/53 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fries 2005*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/20 (10)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laumann 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenoy 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25 (4)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schiopu 2009*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018*: primary Raynaud's</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/57 (7)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018*: secondary Raynaud's</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/65 (18)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/65 (2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*Cross‐over studies: data show the number of events that occurred while on the treatment or control arm regardless of period </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data on withdrawals due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD014089-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on serious adverse advents</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PDE5i</b> </p> <p>Number of events/number of participants (%)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>Number of events/number of participants (%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agarwal 2010</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/26 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herrick 2011</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Andrigueti 2017</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caglayan 2012*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/53 (2)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/53 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fries 2005*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laumann 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shenoy 2010*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schiopu 2009*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/42 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/42 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018: primary Raynaud's*<sup>#</sup> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/54 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/102(0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pfizer 2018: secondary Raynaud's*<sup>#</sup> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/64 (0)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/122 (0.8)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*Cross‐over studies: data show the number of events that occurred while on the treatment or control arm regardless of period<br/><sup>#</sup>Data reported for combined placebo groups (both 4 mg and 20 mg treatment arms) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on serious adverse advents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/full#CD014089-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDE5i vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.07 [‐5.15, ‐1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Duration of attacks (average attack duration, minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.31 [‐8.90, ‐1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Severity of attacks (0 to 10 VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.05 [‐2.68, ‐1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Pain (0 to 10 VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.78, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Patient global assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.59 [‐4.45, ‐2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.17, 5.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Raynaud's Condition Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐1.23, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Parallel RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.31, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Cross‐over: endline changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.26, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Cross‐over: change of changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.45, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Physician global assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.85 [‐3.71, ‐1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Number of people with healed digital ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.05, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Number of people with new digital ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.04, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Myalgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.52, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.36, 3.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PDE5i vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup: primary and secondary Raynaud's phenomenon</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.16 [‐5.04, ‐1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Primary Raynaud's phenomenon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.68 [‐5.09, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Secondary Raynaud's phenomenon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.41 [‐5.58, ‐1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Duration of attacks (average attack duration, minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.54 [‐10.28, ‐2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Primary Raynaud's phenomenon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.59 [‐14.96, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Secondary Raynaud's phenomenon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.62 [‐10.67, ‐2.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup: primary and secondary Raynaud's phenomenon</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup: PDE5i inhibitor type</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.15 [‐5.11, ‐1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.38 [‐10.12, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.69, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.50 [‐6.22, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 PF‐00489791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐4.35, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Duration of attacks (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.48 [‐10.25, ‐2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.49 [‐26.94, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.97 [‐18.45, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.53 [‐20.90, ‐2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 PF‐00489791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.14 [‐6.17, 1.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup: PDE5i inhibitor type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup: sildenafil dosing regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.69, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Sildenafil 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.02 [‐7.61, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Sildenafil 200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.60, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Duration of attacks (average attack duration, minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.97 [‐18.45, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Sildenafil 100 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.11 [‐20.73, ‐5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Sildenafil 200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.60, 0.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup: sildenafil dosing regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup: trial design</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.07 [‐5.15, ‐1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Parallel RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.61 [‐5.02, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Cross‐over: endline changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.49 [‐10.21, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Cross‐over: change of changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐6.28, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Duration of attacks (average attack duration, minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.31 [‐8.90, ‐1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Parallel RCTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.16 [‐24.36, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Cross‐over: endline changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.07 [‐14.34, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Cross‐over: change of changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.98 [‐14.65, 0.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup: trial design</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014089-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis: PDE5i vs placebo (major outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Frequency of attacks (average per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐4.44, ‐0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Duration of attacks (average attack duration, minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.87 [‐8.58, ‐1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Severity of attacks (0 to 10 VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.05 [‐2.68, ‐1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Cross‐over: endline changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.05 [‐2.68, ‐1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Pain (0 to 10 VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.56, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Patient global assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.59 [‐4.45, ‐2.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis: PDE5i vs placebo (major outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014089/references#CD014089-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014089&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014089-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014089-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014089-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014089-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014089-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD014089-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014089-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014089-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014089-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014089"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014089"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014089"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014089\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014089\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014089"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014089&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014089';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014089/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014089/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014089%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716234437"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014089/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716234441"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014089/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9a8a7d6c1bf6',t:'MTc0MDcxNjIzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 